Lv5
1260 积分 2023-06-16 加入
Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China
3天前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
7天前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
8天前
已完结
Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
8天前
已完结
Efficacy and Safety of Programmed Cell Death 1 Inhibitor Monotherapy Versus Chemotherapy as Second-Line Treatment for Advanced Esophageal Cancer: A Meta-analysis and Systematic Review
13天前
已完结
Nimotuzumab: beyond the EGFR signaling cascade inhibition
21天前
已完结
Comparing antibody and small-molecule therapies for cancer
21天前
已完结
Searching for reliable epidermal growth factor receptor response predictors: commentary re M. K. Nyati et al., Radiosensitization by pan-ErbB inhibitor CI-1033 in vitro and in vivo. Clin. Cancer Res., 10: 691-700, 2004
21天前
已完结
Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial
23天前
已关闭
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
23天前
已完结
皖公网安备34019202002308
